Evelo Biosciences Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Evelo Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View analyst ratings for Evelo Biosciences or view top-rated stocks.

Wall Street analysts have given Evelo Biosciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evelo Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Evelo Biosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 2,490,000 shares, an increase of 18.6% from the December 31st total of 2,100,000 shares. Based on an average daily volume of 338,600 shares, the days-to-cover ratio is presently 7.4 days. Approximately 12.8% of the company's stock are sold short.
View Evelo Biosciences' Short Interest.

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Evelo Biosciences.

Evelo Biosciences will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Evelo Biosciences, Inc. (NASDAQ:EVLO) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($0.45) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.05.
View Evelo Biosciences' earnings history.

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EVLO shares have increased by 122.2% and is now trading at $9.71.
View which stocks have been most impacted by COVID-19.

5 brokerages have issued twelve-month price targets for Evelo Biosciences' stock. Their forecasts range from $6.00 to $36.00. On average, they expect Evelo Biosciences' share price to reach $18.25 in the next twelve months. This suggests a possible upside of 88.0% from the stock's current price.
View analysts' price targets for Evelo Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Evelo Biosciences include Revance Therapeutics (RVNC), Pandion Therapeutics (PAND), Madrigal Pharmaceuticals (MDGL), Zentalis Pharmaceuticals (ZNTL), Aurinia Pharmaceuticals (AUPH), Shattuck Labs (STTK), ImmunoGen (IMGN), Seres Therapeutics (MCRB), Kronos Bio (KRON), ADC Therapeutics (ADCT), Ironwood Pharmaceuticals (IRWD), Endo International (ENDP), PMV Pharmaceuticals (PMVP), Organogenesis (ORGO) and Heron Therapeutics (HRTX).
View all of EVLO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Evelo Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Credit Suisse AG (5.70%), BlackRock Inc. (2.74%), Artal Group S.A. (1.47%), Northern Trust Corp (0.48%), Charles Schwab Investment Management Inc. (0.28%) and Bank of New York Mellon Corp (0.12%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences.

EVLO stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, Charles Schwab Investment Management Inc., and Barclays PLC.
View insider buying and selling activity for Evelo Biosciences or view top insider-selling stocks.

EVLO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Artal Group S.A., Credit Suisse AG, JPMorgan Chase & Co., Bank of New York Mellon Corp, Jane Street Group LLC, The Manufacturers Life Insurance Company , and Larson Financial Group LLC. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences or or view top insider-buying stocks.

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVLO stock can currently be purchased for approximately $9.71.

Evelo Biosciences has a market capitalization of $460.93 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.

Evelo Biosciences employs 98 workers across the globe.

The official website for Evelo Biosciences is www.evelobio.com.

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]